Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Madrigal Pharmaceuticals, Inc. - Common Stock (NQ:MDGL)

560.61 -10.84 (-1.90%)
Streaming Delayed Price Updated: 11:37 AM EST, Dec 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Madrigal Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Liver Disease Player 89Bio Downgraded: Analyst Sees Short-Term Uncertainties In Fatty Liver Drug Development ↗
89Bio's journey in the clinical-stage biopharmaceutical space. RBC Capital Markets downgrades with insights on FGF21 drugs, pegozafermin, and 2024 uncertainties. 
Via Benzinga
News headline image
3 Stocks That Could Be Monster Winners in 2024 ↗
Don't be surprised if these three stocks take off in the new year. 
Via The Motley Fool
News headline image
Why Comtech Telecommunications Shares Are Trading Lower By Over 16%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗
Shares of Comtech Telecommunications Corp. (NASDAQ: CMTL) moved lower during Friday’s session following weak quarterly earnings. 
Via Benzinga
News headline image
Analyst Ratings for Madrigal Pharmaceuticals ↗
 
Via Benzinga
News headline image
2 Risky Stocks With Massive Potential ↗
Neither is doing well this year. 
Via The Motley Fool
News headline image
1 Beaten-Down Stock That Could Soar by 86%, According to Wall Street ↗
This company is on the brink of a major breakthrough. 
Via The Motley Fool
News headline image
These 2 Stocks Could Be About to Soar: Are They Buys? ↗
One thing is for certain -- both of these companies are innovators. 
Via The Motley Fool
News headline image
Got $2,000? 3 Growth Stocks to Buy That Could Double Your Money ↗
These stocks just might have investors seeing double over the next few years. 
Via The Motley Fool
News headline image
Can Weight-Loss Drug Ozempic Tip The Scales For Tema's New Healthcare ETF? ↗
New class of weight-reducing drugs underpin launch of exchange-traded fundTema launches healthcare ETF focused on companies researching and treating cardiovascular disease, obesity and diabetes,... 
Via Benzinga
Topics ETFs
News headline image
Madrigal Pharmaceuticals Stock Clears Benchmark, Hits 80+ RS Rating ↗
Madrigal Pharmaceuticals shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 78 to 86. 
Via Investor's Business Daily
News headline image
The 3 Most Undervalued Biotech Stocks to Buy: November 2023 ↗
Given the undervalued biotech industry, these three undervalued biotech stocks to buy are ripe purchase targets for high-potential profits. 
Via InvestorPlace
Madrigal Pharmaceuticals Inc. (NASDAQ: MDGL) is a Leading Gainer in 9/13 Morning Trading
Via Investor Brand Network
News headline image
The Latest Analyst Ratings for Madrigal Pharmaceuticals ↗
 
Via Benzinga
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Nike, Carnival And 3 Stocks To Watch Heading Into Friday ↗
With U.S. stock futures trading higher this morning on Friday, some of the stocks that may grab investor focus today are as follows: 
Via Benzinga
News headline image
Nike, Carnival, Activision Blizzard, Madrigal Pharmaceuticals, Tesla: Why These 5 Stocks Are On Investors' Radars Today? ↗
U.S. stocks traded higher with the Dow Jones gaining over 110 points on Thursday. The Dow traded up 0.35% to 33,666.34 while the NASDAQ rose 0.83% to 13,201.28. 
Via Benzinga
Topics Stocks
News headline image
Wall Street Thinks Madrigal Pharmaceuticals Could Climb 93%. Here's Why It Could Happen Soon. ↗
It has a good shot at commercializing a drug to treat a common liver disease. 
Via The Motley Fool
News headline image
Investors Eye CymaBay's AFFIRM Study As Regulatory Uncertainties Ease ↗
Thursday, CymaBay Therapeutics Inc (NASDAQ: CBAY) initiated the AFFIRM Phase 3b/4 confirmatory study to evaluate the effect of seladelpar on clinical outcomes in patients with compensated cirrhosis due... 
Via Benzinga
News headline image
Madrigal Pharmaceuticals Surges As Its NASH Treatment Toes The Long-Awaited Finish Line ↗
The company is toeing the finish line with a NASH treatment, an area of medicine marked by failures. 
Via Investor's Business Daily
News headline image
Smucker, FuelCell Energy, Granite Ridge Resources And Other Big Stocks Moving Lower On Monday ↗
U.S. stocks traded higher, with the Dow Jones gaining around 100 points on Monday. Here are some big stocks recording losses in today’s session. IHS Holding Limited (NYSE: IHS) shares fell 15.7% to... 
Via Benzinga
Topics Stocks
News headline image
The 3 Best Biotech Stocks to Buy Now: September 2023 ↗
With the biotech sector looking poised to continue its rally further, investors would do well to buy these stocks to capitalize. 
Via InvestorPlace
News headline image
3 Biotech Stocks That Wall Street Analysts Can’t Get Enough Of ↗
Worries about biotech stocks are way overdone, so the sector should make a big comeback in the coming months. 
Via InvestorPlace
News headline image
The 3 Most Promising Pharma Stocks to Own Now ↗
A pillar to economic growth in a defensive area, these promising pharma stocks are set to rise and give investors one bullish ride. 
Via InvestorPlace
News headline image
3 Biotechs Compete for the Same $108-Billion-Dollar Market. Are They a Buy? ↗
NASH treatments are projected to be one of the most sought-after indications in the coming years. 
Via The Motley Fool
News headline image
Looking for the Next Big Biopharma Stock? These 4 Letters Are 1 Big Clue Where to Find It ↗
NASH is a surprisingly common ailment, and the first treatments are on the way. 
Via The Motley Fool
News headline image
Ozempic Could Have a New Multibillion-Dollar Market Opportunity. Is Novo Nordisk Stock a No-Brainer Buy? ↗
Novo Nordisk received some good news in a recent physician survey. 
Via The Motley Fool
News headline image
Madrigal Stock Pops As It Makes Inroads Into What Could Be A $160 Billion Market ↗
Madrigal is working on gaining FDA approval for what could be the first NASH treatment. 
Via Investor's Business Daily
News headline image
Terns Pharmaceuticals Is "Attractively Priced" Despite Pressure From Eli Lilly's Obesity Data, Analyst Says ↗
Tuesday, Terns Pharmaceuticals Inc (NASDAQ: TERN) shares lost more than 25% of their value due to investor pressure it faced after Eli Lilly And Co (NYSE: LLY) announced data from retatrutide that was... 
Via Benzinga
News headline image
Why Walgreens Shares Are Trading Lower By Over 9%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
Gainers Tivic Health Systems, Inc. (NASDAQ: TIVC) shares jumped 105% to $0.2050 after the company signed a distribution agreement with Cardinal Health. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.